AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17171204
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg of elemental iron weekly for 6 months (anemic children)
Trial: 17171204
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg of elemental iron weekly for 6 months (both treated groups)
Trial: 1582642
Drug: Phytogenic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytogenic preparation
Trial: 1582642
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing synthetic substances
Trial: 1582642
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing synthetic substances with corticoid
Trial: 3987543
Drug: Felodipine (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (0.25, 0.75, 1.5 mg)
Trial: 3987543
Drug: Verapamil (2.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (2.0, 4.0, 8.0 mg)
Trial: 3987543
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg) after felodipine and verapamil
Trial: 29284287
Drug: rAd-p53 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rAd-p53 therapy combined with radiotherapy and hyperthermia (p53 group)
Trial: 25343963
Drug: Oral loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loading dose of Vitamin D (500,000 IU) followed by an oral dose of 50,000 IU of Vitamin D monthly for 2 years
Trial: 25343963
Drug: Oral high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high‐dose vitamin D therapy
Trial: 23756453
Drug: Standard Fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Fluid Therapy (Control)
Trial: 15982505
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg co-administered with simvastatin 10 mg or 20 mg
Trial: 15982505
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with simvastatin 10 mg or 20 mg
Trial: 12626793
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural intervention (8-week adjunctive psychological intervention)
Trial: 11097197
Drug: Cocaine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (80 mg/70 kg p.o.)
Trial: 9206191
Drug: Mifepristone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 150 mg in separated doses followed by PG05 1 mg vaginally
Trial: 9206191
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg in single dose followed by PG05 1 mg vaginally
Trial: 29125679
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (TXA) 500 mg in 5 mL
Trial: 28471579
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy plus pharmacological treatment for 21 days
Trial: 22533654
Drug: AZL‐M 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M 40 mg and CLD 25 mg
Trial: 22533654
Drug: AZL‐M 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M 80 mg
Trial: 22533654
Drug: CLD 25
RxNorm normalized name: CldAdo
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLD 25 mg
Trial: 16109117
Drug: Divalproex 500
RxNorm normalized name: DIVALPROEX 500MG 24HR (ER) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex 500 mg/day
Trial: 16109117
Drug: Divalproex 1000
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex 1000 mg/day
Trial: 16109117
Drug: Divalproex 1500
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex 1500 mg/day
Trial: 12145720
Drug: Levofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (750 mg once per day)
Trial: 12145720
Drug: Ticarcillin-clavulanate (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin-clavulanate (3.1 g iv every 4-6 hours) followed by amoxicillin-clavulanate (875 mg orally every 12 hours)
Trial: 11026121
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment (MMP) with adjunctive manual-guided psychosocial group interventions
Trial: 11026121
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment (MMP)
Trial: 8477058
Drug: Regimen S1
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen S1 (cranial irradiation 18 Gy and intrathecal chemotherapy starting at 5 weeks)
Trial: 8477058
Drug: Regimen S2
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen S2 (cranial irradiation and intrathecal chemotherapy starting at 24 weeks)
Trial: 23192720
Drug: Compelled body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compelled body weight shift (CBWS) therapy combined with physical therapy
Trial: 20384426
Drug: Alcohol (0.84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.84 g/kg for men, 0.76 g/kg for women)
Trial: 15818329
Drug: Conventional immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppressive treatment
Trial: 18479175
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg/day
Trial: 15225178
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg/day
Trial: 28602413
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy and Radiation Therapy (HT-RT)
Trial: 25542519
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tears
Trial: 21235700
Drug: Solifenacin (5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5/10 mg)
Trial: 11447543
Drug: Dilute epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilute epinephrine irrigation (0.33 mg/L)
Trial: 8056798
Drug: RD heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RD heparin administered twice daily (50 anti-factor-Xa units/kg, subcutaneously, twice daily)
Trial: 8056798
Drug: RD heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RD heparin administered once daily (90 anti-factor-Xa units/kg, subcutaneously, once daily)
Trial: 8056798
Drug: Warfarin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (5 mg orally preoperatively, adjusted daily)
Trial: 3052556
Drug: Nalbuphine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 60 mg
Trial: 3052556
Drug: Nalbuphine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 30 mg
Trial: 412800
Drug: Dihydrocodeine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine 30 mg
Trial: 21388622
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ) supplement (300 mg/day)
Trial: 19016091
Drug: Clinician-assisted computerized
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-assisted computerized cognitive behavioural treatment (CaCCBT)
Trial: 10911512
Drug: Zaleplon 10
RxNorm normalized name: zaleplon 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon 10 mg alone
Trial: 10911512
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg alone
Trial: 10911512
Drug: Zaleplon 10
RxNorm normalized name: zaleplon 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon 10 mg and Ibuprofen 600 mg concomitantly
Trial: 10911512
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg and Zaleplon 10 mg concomitantly
Trial: 1598509
Drug: Ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin treatment at 6-month intervals for two years
Trial: 1598509
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment at 6-month intervals for two years
Trial: 6427820
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine (IMI) administered orally
Trial: 6427820
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine (IMI) administered intramuscularly
Trial: 20339879
Drug: Landiolol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Landiolol infusion (0.125 mg/kg/min for 1 min, then 0.01‐0.04 mg/kg/min until 6 h after anesthesia)
Trial: 18525385
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (usual care)
Trial: 12771001
Drug: Apolipoprotein A-I/phosphatidylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apolipoprotein A-I/phosphatidylcholine (apoA-I/PC) disks infusion
Trial: 6329395
Drug: Misonidazole administered
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole administered 4 to 5 hours before each fraction of radiotherapy (total of 11 to 13 g/m2)
Trial: 6329395
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 4 to 5 hours before each fraction of radiotherapy
Trial: 17032099
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) plus contingency management (CM)
Trial: 17032099
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) without CM
Trial: 17032099
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling (DC) plus CM
Trial: 12775205
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment (20 min)
Trial: 11816733
Drug: Activelle (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activelle (1 mg 17 beta‐estradiol combined with 0.5 mg norethisterone acetate)
Trial: 2887430
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous streptokinase (1.5 MU over one hour)
Trial: 2887430
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin (325 mg on alternate days for 28 days)
Trial: 2887430
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (1000 IU h‐1 for 48 hours)
Trial: 28708221
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) intravitreal implant
Trial: 26396166
Drug: Client-centred, activities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centred, activities of daily living intervention
Trial: 26396166
Drug: Usual activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual activities of daily living
Trial: 25919281
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (common drugs only)
Trial: 22123359
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Conivaptan and Furosemide
Trial: 19447264
Drug: Chiropractic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic treatment at L5 using manually assisted mechanical force (Activator)
Trial: 19447264
Drug: Chiropractic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic treatment at L5 using traditional diversified technique spinal manipulation
Trial: 19447264
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment in pain-free group
Trial: 19447264
Drug: Treatment pain-free
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment pain-free group
Trial: 19447264
Drug: Treatment pain
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment pain group
Trial: 12165576
Drug: SLI381 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 10 mg
Trial: 12165576
Drug: SLI381 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 20 mg
Trial: 12165576
Drug: SLI381 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 30 mg
Trial: 9564199
Drug: Adderall 10
RxNorm normalized name: Adderall 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall 10 mg
Trial: 9174180
Drug: Praziquantel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (25 mg/kg) administered alone
Trial: 9174180
Drug: Praziquantel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (25 mg/kg) administered with cimetidine
Trial: 1606596
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate 3.75 mg every 4 weeks (n = 9)
Trial: 1606596
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate 7.5 mg every 4 weeks (n = 16)
Trial: 1606596
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate 7.5 mg monthly injections (postmenopausal study, n = 15)
Trial: 1606596
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate (both doses)
Trial: 3022036
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus chest irradiation (40 Gy between cycles 1 and 2)
Trial: 3022036
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus chest irradiation
Trial: 24036024
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous cardiosphere-derived cells (CDCs) (12.5 to 25 × 10(6))
Trial: 22854401
Drug: Sucrose with
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose with whole blackcurrants (150 g served as purées) and 35 g added sucrose
Trial: 22854401
Drug: Sucrose with
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose with lingonberries (150 g served as purées) and 35 g added sucrose
Trial: 22854401
Drug: Sucrose with
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose with blackcurrant nectar (300 mL) and 35 g added sucrose
Trial: 22854401
Drug: Sucrose with
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose with lingonberry nectar (300 mL) and 35 g added sucrose
Trial: 22854401
Drug: Sucrose alone
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose alone (35 g in 300 mL water)
Trial: 17145527
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy (CT)
Trial: 17145527
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) with concurrent chemotherapy (CT)
Trial: 14505262
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) and tibolone (2.5 mg per day) for 3-6 months
Trial: 14505262
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) with add-back therapy of norethindrone acetate (5 mg per day) from the first day of treatment
Trial: 11225744
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous oestradiol (2.0 mg) + norethisterone acetate (1.0 mg) per day
Trial: 11225744
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal oestrogen‐only (50 mg/day)
Trial: 31255574
Drug: MDCK-derived H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCK-derived H5N1 alum-adjuvanted vaccine (0.5 mL, 7.5, 15, or 30 μg of hemagglutinin)
Trial: 31255574
Drug: MDCK-derived H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCK-derived H5N1 alum-adjuvanted vaccine (30 μg HA)
Trial: 31255574
Drug: MDCK-derived H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCK-derived H5N1 alum-adjuvanted vaccine
Trial: 25702876
Drug: Short-term androgen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term androgen deprivation (4 months) with high-dose radiotherapy (76-82 Gy)
Trial: 25702876
Drug: Long-term androgen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term androgen deprivation (24 months) with high-dose radiotherapy (76-82 Gy)
Trial: 23800573
Drug: Citalopram 20mg
RxNorm normalized name: Escitalopram 20mg Oral tablet
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram 20mg once daily (n=38)
Trial: 21557525
Drug: Rituximab 500
RxNorm normalized name: riTUXimab 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 500 mg plus MTX
Trial: 21557525
Drug: Rituximab 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 1,000 mg plus MTX
Trial: 21557525
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus MTX (both doses)
Trial: 16741262
Drug: Arginine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine (7 g)
Trial: 3544622
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg/day)
Trial: 25174679
Drug: Anthelminthic drug
RxNorm normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthelminthic drug administration
Trial: 18637983
Drug: Feeding assistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding assistance intervention (twice per day, 5 days per week for 24 weeks)
Trial: 17133204
Drug: DAART (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAART (self-administered therapy)
Trial: 10890645
Drug: Volume Assist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume Assist (VA) at 8 cm H2O/L and 12 cm H2O/L
Trial: 8684741
Drug: Concentrated oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated oxytocin infusion plus 10-mg PGE2 vaginal suppository every 6 hours
Trial: 8684741
Drug: 20-mg PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20-mg PGE2 vaginal suppository every 4 hours
Trial: 24660645
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (laser simulation)
Trial: 22345050
Drug: Test mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test mirtazapine 30 mg single-dose formulation
Trial: 20412743
Drug: Cholesterol metabolism
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol metabolism modulation
Trial: 20412743
Drug: Essential cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential cholesterol modulators (e.g., ATP‐binding cassette transporter A1, LDL receptor)
Trial: 18052562
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg twice daily) for 4 weeks
Trial: 16135679
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose inhaled corticosteroids (fluticasone propionate 200 mug/day) plus salmeterol